November 1, 2002Expert Opinion on Pharmacotherapy
Clinical treatment regimens for chronic heart failure: a review
Key result
Pharmacotherapy for chronic heart failure, including ACE inhibitors, beta-blockers, and spironolactone, provides established mortality and morbidity benefits based on a large evidence base.
Population
Patients with chronic heart failure (CHF)
Design
Review
Authors
Discussion
Loading...
Member takes
Implication
Reinforces foundational HF pharmacotherapy; confirms large RCT benefits while leaving device integration questions open for trials.
Structured PICO
P
Population
Patients with chronic heart failure (CHF)
I
Intervention
Pharmacotherapy (including angiotensin-converting enzyme inhibitors, beta-blockers, and spironolactone) and device therapies (biventricular pacing, mechanical hearts)
This review summarizes the evidence-based treatment approaches for chronic heart failure, highlighting the roles of pharmacotherapy and emerging device therapies.
Cite This Study
Gould et al. (2002) conducted a review in Chronic heart failure. Pharmacotherapy (ACE inhibitors, beta-blockers, spironolactone) and biventricular pacing was evaluated. Pharmacotherapy for chronic heart failure, including ACE inhibitors, beta-blockers, and spironolactone, provides established mortality and morbidity benefits based on a large evidence base.